24-12-2020 | 15:38 PM
First mRNA vaccine of India
HGC019 Vaccine was developed by Gennova Biopharmaceuticals based in Pune. It is the country's first natively developed mRNA vaccine.
Phase I and Phase II clinical trials of the vaccine have recently been authorised by the Indian Medicine Controller General.
About HGC019 Vaccine:
The vaccine uses the same platform as that used for the vaccines COVID-19 developed by Pfizer and Moderna. The HGC019 vaccine was developed in conjunction with the U.S. HDT Biotech Corporation.
The vaccine does not use the traditional model to induce an immune response. Instead, it uses molecular guidance to create proteins in the body via synthetic RNA.
The vaccine is stable at 2-8 degrees centigrade. Vaccine is funded by seed grants under the Ind-CEPI mission:
Ind-CEPI Mission:
The mission seeks to improve the production of vaccines for emerging infectious diseases. The policy encourages the creation of at least two or three new vaccines amid epidemic challenges. Funding is given until phase II of the Vaccine Testing.
Supports capacity building and the growth of skills. Strengthens the infrastructure to meet vaccine production needs.
Note:
MRNA vaccines are considered healthy because they are non-integrating in nature, non-infectious and destroyed by normal cellular pathways. They are synthetic and therefore do not need a host for development, such as eggs, bacteria, etc.
